Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
暂无分享,去创建一个
F. Tas | H. Alış | M. Karabulut | M. Gonenc | S. Karabulut | Ç. Usul Afşar | M. Serilmez | N. Dagoglu